Contractile responses of human thyroid arteries to vasopressin by Vila Salinas, José María et al.
Life Sciences 93 (2013) 525–529
Contents lists available at ScienceDirect
Life Sciences
j ourna l homepage: www.e lsev ie r .com/ locate / l i fesc ieContractile responses of human thyroid arteries to vasopressin
José M. Vila a,c, Martín Aldasoro a,c, Gloria Segarra a,c, Juan B. Martínez-León b, María Dolores Mauricio a,c,
Salvador Lluch a,c, Pascual Medina a,c,⁎
a Departamento de Fisiología, Universidad de Valencia, 46010 Valencia, Spain
b Servicio de Cirugía Cardiaca, Hospital General de Valencia, 46014 Valencia, Spain
c Instituto de Investigación Sanitaria INCLIVA, Hospital Clínico Universitario, 46010 Valencia, Spain⁎ Corresponding author at: Departamento de Fisiología, Fac
Universidad de Valencia, Av. Blasco Ibañez 15, 46010 Valen
fax: +34 963864642.
E-mail address: Pascual.Medina@uv.es (P. Medina).
0024-3205/$ – see front matter © 2013 Elsevier Inc. All ri
http://dx.doi.org/10.1016/j.lfs.2013.08.019a b s t r a c ta r t i c l e i n f oArticle history:
Received 28 May 2013
Accepted 20 August 2013
Keywords:
Endothelium
Human thyroid artery
Nitric oxide
Vasopressin V1-receptor
Aims: In the present study we investigated the intervention of nitric oxide and prostacyclin in the responses to
vasopressin of isolated thyroid arteries obtained from multi-organ donors.
Main methods: Paired artery rings from glandular branches of the superior thyroid artery, one normal and the
other deendothelised, were mounted in organ baths for isometric recording of tension. Concentration–
response curves to vasopressin were determined in the absence and in the presence of either the vasopressin
V1 receptor antagonist d(CH2)5Tyr(Me)AVP (10−8 M), the nitric oxide synthase inhibitor NG-monomethyl-L-
arginine (L-NMMA, 10−4 M), or the inhibitor of prostaglandins indomethacin (10−6 M).
Key ﬁndings: In artery rings under resting tension, vasopressin produced concentration-dependent, endothelium-
−8independent contractions. The vasopressin V1 receptor antagonist d(CH2)5Tyr(Me)AVP (10 M) displaced the
control curve to vasopressin 19-fold to the right in a parallelmanner. The contractile response to vasopressinwas
unaffected by L-NMMA or by indomethacin.
Signiﬁcance:Vasopressin causes constriction of human thyroid arteries by stimulation of V1 vasopressin receptors
located on smooth muscle cells. These effects are not linked to the presence of an intact endothelium or to the
release of nitric oxide or prostaglandins. The constriction of thyroid arteries may be particularly relevant in cer-
tain pathophysiological circumstances in which vasopressin is released in amounts that could interfere with the
blood supply to the thyroid gland.© 2013 Elsevier Inc. All rights reserved.Introduction
Vasopressin is a neuropeptide that promotes reabsorption of
water in renal tubular cells through vasopressin-V2 receptors and
produces contraction of vascular smooth muscle through vasopressin-
V1 receptors (Michell et al., 1979; Penit et al., 1983; Barrett et al.,
2007). With regard to human vessels, vasopressin causes powerful V1
receptor-mediated constriction in isolated mesenteric (Ohlstein and
Berkowitz, 1986; Martínez et al., 1994b), cerebral (Lluch and Gómez,
1987; White and Robertson, 1987) and renal (Medina et al., 1996b) ar-
teries. This effect is endothelium-independent and due to direct stimu-
lation of receptors located on smooth muscle cells (Martín de Aguilera
et al., 1990; Martínez et al., 1994a, b). Both hyperthyroidism and hypo-
thyroidism are associated with marked effects on the cardiovascular
system including changes in cardiac output, blood pressure, and sys-
temic vascular resistance (Klein and Ojamaa, 2001). On the otherultad deMedicina y Odontología,
cia, Spain. Tel.:+34 963864983;
ghts reserved.hand, impaired thyroid function is accompanied by changes in plasma
vasopressin levels (Arnaout et al., 1992; Marcisz et al., 2001) that
might be responsible for constriction of thyroid vessels. The effects of
vasopressin in these arteries are not fully known. Such data might be
of pathophysiological signiﬁcance in those states characterised by in-
creased plasma vasopressin levels, such as haemorrhagic and septic
shock (Landry et al., 1997; Tsuneyoshi et al., 2003) and in some patients
with congestive heart failure (Rouleau et al., 1994; Goldsmith and
Gheorghiade, 2005). Studies from our laboratory have shown that in
human thyroid arteries frommultiorgan donors the endotheliummod-
ulates responses to acetylcholine and noradrenaline through the release
of nitric oxide (NO), an endothelium-derived relaxing factor (Torondel
et al., 2004; Ortega et al., 2005). Moreover, NO production is decreased
in hyperthyroid patients when compared with control subjects
(Hermenegildo et al., 2002). These results strongly suggest that endo-
thelial NO might play a key role in the responsiveness of thyroid ar-
teries to speciﬁc pharmacological interventions. Accordingly, the
aim of the present study was to determine the effects of vasopressin
in human thyroid arteries obtained from multiorgan donors. Obser-
vations were made in the presence and in the absence of endothelium
and after exposure to NG-monomethyl-L-arginine (L-NMMA), an in-
hibitor of NO synthase, or the vasopressin V1 receptor antagonist
d(CH2)5Tyr(Me)AVP.
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Subjects
Glandular branches of the superior thyroid artery were obtained
from12multiorgandonors during procurement of organs for transplan-
tation (8 men and 4 women; age range: 22–65 years; cause of death: 7
head trauma, 2 intracranial haemorrhage, 3 myocardial infarction). The
study was approved by the ethical committee of our institution. The
vessels were immediately placed in a Petri dish containing refrigerated
(4 °C) modiﬁed Krebs–Henseleit solution of the following mM compo-
sition: NaCl, 115; KCl, 4.6; KH2PO4, 1.2; MgCl2·6H2O, 1.2; CaCl2, 2.5;
NaHCO3, 25; glucose 11.1 and disodium EDTA, 0.01.
In vitro experiments
Experiments started within 2 h, or not more than 8 h after organs
were removed. When used within 2 to 8 h, the vessels were stored in
the 4 °C modiﬁed Krebs-Henseleit solution, which was found not to
alter either the endothelium-dependent relaxation to acetylcholine or
the contractile response to KCl or vasopressin. Arteries were cleaned
of connective tissue and cut into rings (3 mm in length, 1 to 1.5 mm
outer diameter) under a dissecting microscope. In some experiments,
the endothelium was removed mechanically by inserting a roughened
stainless-steel wire into the lumen and gently rolling the vessel ring
on wet ﬁlter paper. Each ring was suspended between two stainless-
steel L-shaped pins in 4-mL organ baths containing modiﬁed Krebs-
Henseleit solution. The solution was equilibrated with 95% oxygen
and 5% carbon dioxide to give a pH from 7.3 to 7.4 and maintained at
37 °C with a circulating water jacket and a heat pump. One pin was
ﬁxed to the organ bath wall and the other was connected to a strain
gauge (model FT03; Grass Instrument Division of Astro-Med Inc.,
West Warwick, RI). Changes in isometric force were recorded on a
Macintosh computer (Apple Computer, Cupertino, CA, USA) by use of
Chart version 3.4/s software and a MacLab/8e data acquisition system
(ADInstruments, Mountain View, CA, USA). To establish the resting
tension for maximal force development, we performed a series of
preliminary experiments on thyroid artery rings which were exposed
repeatedly to 100 mM KCl. Basal tension was increased gradually until
contractions were maximal. The optimal resting tension was 10 mN.
The rings were allowed to attain a steady level of tension during a 2-
to 3-hour accommodation period before testing. The contractile re-
sponse to 100 mM KCl was similar in intact and denuded arteries
(24.7 ± 4.8 versus 23.9 ± 4.1 mN; n = 8, P N 0.05).
Functional integrity of the endothelium was conﬁrmed routinely by
the presence of relaxation induced by acetylcholine (10−7 to 10−6 M)
during contraction obtained with noradrenaline (10−6 to 3 × 10−6 M).
Arteries in which the acetylcholine reversed the noradrenaline-
induced tone by more than 70% were designated as endothelium intact
and arteries in which acetylcholine caused less than 15% relaxation
were designated as denuded.
Concentration–response curves to vasopressin were determined in
a cumulativemanner under the following conditions: (1) in the absence
of inhibitors (control response); (2) in the presence of the V1-receptor
antagonist 1-(β-mercapto-β,β-cyclopentamethylene-propionic acid)
2-(O-methyl)-tyrosine, 8-arginine) vasopressin (d(CH2)5Tyr(Me)AVP,
10-8 M); (3) in the presence of L-NMMA (10−4 M) to inhibit NO
synthase; and (4) in the presence of indomethacin (10−6 M) to inhibit
the production of PGI2. Control (in the absence of inhibitors) and exper-
imental (after incubation for 20 min with inhibitors) responses were
obtained from separate artery rings.
Chemicals
All substances were purchased from Sigma Chemical Co. (St. Louis,
MO, USA).Data analysis
All values are expressed as means ± SEM. Contractile effects were
expressed as a percentage of the response to KCl (100 mM). EC50 values
(concentration of agonist producing half-maximum effect) were
expressed as pD2 (− log EC50). The maximum contractions and pD2
values were compared by one-way analysis of variance (ANOVA) with
the Bonferroni test as post hoc test. n values are presented as the num-
ber of donors. Statistical signiﬁcance was accepted at P b 0.05.
Results
KCl (100 mM) produced a sustained contraction with a maximal ef-
fect of 24.3 ± 3.1 mN (Fig. 1). In precontracted arteries with noradrena-
line (10−6 M), acetylcholine (10−6 M) caused relaxation in arterieswith
an intact endothelium, but was abolished in endothelium-denuded rings
(Fig. 1). Cumulative application of vasopressin produced a constrictor re-
sponse that was concentration-dependent (Fig. 1). The maximum ten-
sion developed as well as the pD2 were similar (P N 0.05) in arterial
segments with and without endothelium (Fig. 1 and Table 1). The pres-
ence of the vasopressin V1-selective receptor antagonist d(CH2)5Tyr(Me)
AVP (10−8 M) in the organ bath shifted the concentration–response
curve to vasopressin 19-fold (P b 0.05) to the right in a parallel manner,
but differences in themaximum tensions developedwere not signiﬁcant
(P N 0.05) (Fig. 1D and Table 1).
The presence of L-NMMA (10−4 M) did not change signiﬁcantly
(P N 0.05) the concentration–response curve for vasopressin (Fig. 2 and
Table 1). However, L-NMMA decreased acetylcholine-induced relaxation
in artery rings precontracted with noradrenaline (10−6−3 × 10−6 M),
thus showing the ability of these vessels to display NO-mediated relaxa-
tion (Fig. 2B). Arteries exposed to indomethacin (10−6 M) did not show
signiﬁcant changes in the contractile response to vasopressin (Fig. 2 and
Table 1).
Discussion
Our results indicate that vasopressin is a potent agonist for the con-
traction of thyroid vascular smoothmuscle through activation of specif-
ic V1-vasopressin receptors. The maximum tensions with respect to KCl
response and sensitivity (in terms of pD2 values) attained with vaso-
pressin in thyroid arteries are within the range of values obtained in
other human arteries (Medina et al., 1997; Aldasoro et al., 2008) but
higher than the corresponding values in human saphenous vein
(Aldasoro et al., 1997; Medina et al., 1997).
The functional properties of the endothelium–NO system of
human thyroid arteries remain largely unexplored. NO synthase,
the enzyme responsible for the formation of NO (Palmer et al.,
1988) is present in the thyroid follicular cells and in endothelial
cells of the human thyroid gland (Colin et al., 1997), and human
thyrocites produce the endogenous NO synthase inhibitor asymmet-
ric dimethylarginine (ADMA) (Colin et al., 1995; Millatt et al., 2000).
In addition, NO modulates the response of human thyroid arteries to
acetylcholine and noradrenaline (Torondel et al., 2004). Previously,
we have demonstrated in human thyroid arteries that treatment
with L-NMMA reduces the endothelium-dependent relaxation to
acetylcholine. The NO component, sensitive to L-NMMA, accounted for
approximately 20% of the maximum relaxation to acetylcholine. The NO-
independent relaxation results from the release by acetylcholine of
endothelium-dependent hyperpolarizing factor (EDHF). The EDHF
component involves activation of Ca2+-dependent K+ channels,
sensitive to charybdotoxin and apamin (Torondel et al., 2004).
All these results are consistent with a role for NO in responsiveness
of thyroid arteries. However, the intervention of NO seems to be re-
stricted to speciﬁc pharmacological receptors. Indeed the present ex-
periments show that the vasopressin-induced contraction is not
linked to the presence of an intact endothelium. The evidence for this
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Fig. 1. Effects of vasopressin in human thyroid artery. Recordings illustrating the effects of KCl (100 mM), noradrenaline (NA, 10−6 M), acetylcholine (ACh, 10−6 M) and vaso-
pressin (10−11–10−6 M) in thyroid artery rings A) with and B) without endothelium, and C) in the presence of 10−8 M of the vasopressin V1 receptor antagonist d(CH2)5Tyr(Me)AVP.
Points mark time of addition of drugs and (W)marks washout. D) Concentration–response curves for vasopressin in arterial rings with (●, n = 7) andwithout (○, n = 6) endothelium,
and in the presence of 10−8 M of the vasopressin V1 receptor antagonist d(CH2)5Tyr(Me)AVP (□, n = 6); results are expressed as a percentage of the contraction developed by 100 mM
KCl. Values are means ± SEM.
527J.M. Vila et al. / Life Sciences 93 (2013) 525–529is that the contraction was similar in intact and endothelium-denuded
arteries. In agreement with the present results, previous experiments
have shown that vasopressin causes endothelium-independent con-
traction in several human arteries (Martínez et al., 1994a, b; Medina
et al., 1996b; Segarra et al., 1998). Furthermore, the contraction does
not involve the intervention of the L-arginine-NO pathway because
L-NMMA, a selective inhibitor of NO synthase, did not modify the
vasopressin-induced contraction. The present results are consistent
with previous data showing that NO synthase inhibition does not af-
fect the vasopressin-induced contractions in human arteries
(Medina et al., 1996a,b). However, in vitro and in vivo experiments
indicate that a considerable regional heterogeneity exists in the re-
activity of blood vessels to vasopressin. In isolated rabbit saphenous,
coronary and renal arteries, and to a minor degree in basilar arteries,
the endothelium has an inhibitory effect on the vasoconstriction in-
duced by vasopressin mediated by the release of NO (García-Villalón
et al., 1996).
As vasopressin has been reported to induce vasodilating prostaglan-
din synthesis via a V1 receptor-dependent pathway (Nakatani et al.,Table 1
pD2 values and maximum contractions (Emax) to vasopressin in the different
experimental conditions in segments of human thyroid arteries.
Artery rings pD2 Emax (%)
With endothelium (n = 7) 8.97 ± 0.25 88 ± 6
Without endothelium (n = 6) 8.93 ± 0.24 90 ± 5
L-NMMA (10−4 M) (n = 5) 9.00 ± 0.19 95 ± 7
Indomethacin (10−6 M) (n = 5) 8.87 ± 0.21 78 ± 5
d(CH2)5Tyr(Me)AVP (10−8 M) (n = 6) 7.69 ± 0.33⁎ 77 ± 7
n = number of donors; pD2 = negative logarithm of molar concentration required to
produce half-maximum response. Emax is expressed as a percentage of responses to
100 mM KCl. Values are mean ± SEM.
⁎ P b 0.05 vs artery segments with endothelium.2007) it might be expected that cyclooxygenase inhibitors canmodulate
the responses to vasopressin. Indomethacin potentiates the vasopressin-
induced contraction in human mesenteric (Martínez et al., 1994b) and
renal (Medina et al., 1996b) arteries with or without endothelium, thus
suggesting that relaxant prostaglandins, derived mainly from smooth
muscle cells, attenuate the V1-mediated contractile effect of vasopressin.
However, contractile responses of human thyroid artery to vasopressin
were unaffected by cyclooxygenase inhibition, thus suggesting that in
this vessel, vasopressin does not stimulate the release of prostanoids. A
common ﬁnding in the vascular effects of vasopressin is the heterogene-
ity of responsiveness, depending on regional and species differences
(García-Villalón et al., 1996). Therefore, it is likely that the contractile ef-
fects of vasopressin in thyroid arteries are due to direct stimulation of
speciﬁc receptors located on smooth muscle cells.
d(CH2)5Tyr(Me)AVP has been reported to be a potent inhibitor of
the contractile response to vasopressin in human arteries (Martínez
et al., 1994a,b; Medina et al., 1996b; Segarra et al., 1998). Furthermore,
this compound does not interfere with the vasoconstrictor response to
angiotensin II, noradrenaline or KCl (Ohlstein and Berkowitz, 1986;
Fox et al., 1987). The present results show that d(CH2)5Tyr(Me)AVP is
an effective antagonist of the response to vasopressin in human thyroid
arteries. At 10−8 M, the antagonist produced a 19-fold shift to the right
of the control concentration–response curve to vasopressin, presum-
ably due to a competitive agonist–antagonist interaction.
Plasma levels of vasopressin increase in response to stimuli such as
increased plasma osmolality (Mason, 1980), dehydration, hypotension
(Sorenson and Hammer, 1985), exercise (Melin et al., 1980), increased
angiotensin II levels (Bonjour and Malvin, 1970), and sympathetic acti-
vation (Leng et al., 1999) and in different pathophysiological settings
such as, haemorrhage (Fujisawa et al., 1994), and congestive heart
failure (Preibisz et al., 1983). In addition, vasopressin may modify the
effects of other vasoactive substances that are found in plasma or re-
leased from perivascular nerve endings. Several studies have reported
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Fig. 2.Recordings illustrating the effects of noradrenaline (NA, 10−6 M), acetylcholine (ACh, 10−6 M) and vasopressin (10−11–10−7 M) in thyroid artery ringswith endotheliumA) in the
absence andB) in the presence of L-NMMA (10−4 M) or C) indomethacin (10−6 M). D) Responses to vasopressin in the absence (●, n = 7) and in the presence of 10−4 M of L-NMMA (□,
n = 5) or 10−6 M of indomethacin (Δ, n = 5); results are expressed as a percentage of the contraction developed by 100 mM KCl. Values are means ± SEM.
528 J.M. Vila et al. / Life Sciences 93 (2013) 525–529a signiﬁcant augmentation by vasopressin of the vasoconstricting action
of catecholamines (Medina et al., 1997; Segarra et al., 1998). Conse-
quently, the vascular effects of vasopressin on thyroid arterymay be par-
ticularly relevant in those states characterised by increased vasopressin
plasma levels as well as in those clinical situations, such as asystolic car-
diac arrest, refractory arterial hypotension during anaesthesia, septic
shock, or oesophageal variceal haemorrhage, in which vasopressin and
synthetic vasopressin receptor agonists are used as a therapeutic tool
(Treschan and Peters, 2006). Under these conditions the contractile re-
sponse of the thyroid artery induced by vasopressin may reduce thyroid
blood ﬂow and thyroid hormone release. Interestingly, along with in-
creased levels of vasopressin, low thyroid hormone circulating levels
have been described in patients with heart failure (Hamilton et al.,
1990) and are associated with poor prognosis (Iervasi et al., 2003).
These ﬁndings suggest a potential link between the vasoconstrictive ef-
fects of vasopressin on thyroid arteries and low plasmatic thyroid hor-
mone concentrations associated with unfavourable outcomes of these
patients. Nevertheless, we cannot deduce from our observations wheth-
er disease-related increases in plasma vasopressin would reduce thyroid
blood ﬂow enough to signiﬁcantly affect thyroid function. Future studies
will therefore be needed to deﬁne the role of vasopressin in the regula-
tion of thyroid blood ﬂow.
In view of the speciﬁcity and potency of the vasopressin V1-
receptor antagonist d(CH2)5Tyr(Me)AVP, it seems appropriate to
consider the use of vasopressin receptor antagonists as a potentially
beneﬁcial therapeutic approach in circumstances in which vasopres-
sin plasma concentrations are markedly raised (e.g. congestive heart
failure). Indeed, several vasopressin antagonists, orally active in
humans, are presently undergoing clinical development (Arai et al.,
2007).Conclusions
Our study shows that vasopressin exerts a powerful constrictor
action on isolated human thyroid arteries by direct stimulation of
V1-vasopressin receptors located on smooth muscle cells. It appearsthat in these arteries the contractile response to vasopressin is not
modulated by the NO and cyclooxygenase pathways.
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